Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DS69NO
|
|||
| Drug Name |
Nipocalimab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Myasthenia gravis [ICD-11: 8C6Y] | Phase 3 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20; ICD-9: 729] | Phase 2 | [2] | ||
| Company |
Janssen Research & Development Raritan, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin Fc receptor (FCR) | Target Info | Antagonist | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04951622) Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04991753) A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants With Active Rheumatoid Arthritis Despite Standard Therapy. U.S.National Institutes of Health. | |||
| REF 3 | Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs. 2022 Jun;82(8):865-887. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.